Although there is growing interest in developing PPARβ/δ agonists to treat dyslipidemia, no PPARβ/δ compound has been brought to market, and the role of this isotype in tumourigenesis has been debated (Michalik et al, 2004; Peters & Gonzalez, 2009; Peters et al, 2012). The gene discussed is PPARD; the disease is metabolic syndrome.